J. Smerage

发表

Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety.

D. Hayes, S. Lo, P. Mumby, 2009 .

NCCN Clinical Practice Guidelines Occult primary.

D. Ettinger, A. Rashid, D. Gierada, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Robert B Livingston, Gordan Srkalovic, Brian Leyland-Jones, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cells.

D. Hayes, J. Smerage, 2010, Progress in molecular biology and translational science.

Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study

G. Hortobagyi, W. Barlow, D. Hayes, 2019, Clinical Cancer Research.

New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.

Lesly A. Dossett, J. Griggs, C. Brummett, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementing circulating tumor cells in routine practice of breast cancer management: overview of the interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2013 .

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

E. Winer, B. Leyland-Jones, R. Livingston, 2013 .

Is There aR ole for CirculatingTumor Cells in the Management of Breast Cancer

D. Hayes, J. Smerage, 2008 .

The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer: SECTION II: MOLECULAR AND CELLULAR MARKERS OF PROGNOSIS

D. Hayes, J. Smerage, 2007 .

Pilot study of duloxetine for treatment of aromatase inhibitor‐associated musculoskeletal symptoms

J. Griggs, M. Banerjee, M. Wicha, 2011, Cancer.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

S. Sleijfer, L. Esserman, B. Naume, 2018, Journal of the National Cancer Institute.

Activation mechanism of the multifunctional transcription factor repressor-activator protein 1 (Rap1p)

H. Baker, J. Smerage, M. C. López, 1996, Molecular and cellular biology.

Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?

Daniel F. Hayes, D. Hayes, J. Smerage, 2008, Clinical Cancer Research.

Prognostic Implications of CTC in Breast Cancer

J. Smerage, 2016 .

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

T. Fehm, M. Piccart, M. Ignatiadis, 2012, Cancer and Metastasis Reviews.

A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography

M. Banerjee, D. Hayes, V. Stearns, 2010, Cancer.

Association of Aromatase Inhibitor-Associated Musculoskeletal Symptoms with Ultrasonographic Changes at the Wrist.

M. Banerjee, D. Hayes, V. Stearns, 2009 .

Occult primary, version 3.2014; Featured updates to the NCCN guidelines

D. Ettinger, A. Rashid, D. Gierada, 2014 .

Occult primary, version 3.2014.

D. Ettinger, A. Rashid, D. Gierada, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer

G. Hortobagyi, L. Pusztai, W. Barlow, 2023, JCO precision oncology.

The measurement and therapeutic implications of circulating tumour cells in breast cancer

D. Hayes, J. Smerage, D F Hayes, 2005, British Journal of Cancer.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

D. Hayes, K. Albain, P. Mumby, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer

D. Hayes, G. Doyle, M. Miller, 2013, Molecular oncology.

The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer

Daniel F Hayes, D. Hayes, J. Smerage, 2008, Cancer investigation.

Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.

David A. Williams, K. Griffith, S. Harte, 2014, The journal of pain : official journal of the American Pain Society.

Clinical Applications of Circulating Tumor Cells in Breast Cancer.

D. Hayes, J. Smerage, C. Paoletti, 2019, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Multiple domains of repressor activator protein 1 contribute to facilitated binding of glycolysis regulatory protein 1.

H. Baker, J. Smerage, M. C. López, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center

K. Cooney, P. Boonstra, M. Ison, 2017, Journal of Cancer Education.

Low-cost stepped intervention to increase influenza vaccination rates at a Comprehensive Cancer Center.

K. Cooney, P. Boonstra, M. Ison, 2015 .

Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection

D. Hayes, S. Lo, P. Mumby, 2007 .

Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop

W. Jusko, H. Eichler, F. Goodsaid, 2011, The AAPS Journal.

Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer

J. Griggs, M. Banerjee, M. Rubenfire, 2015, Breast Cancer Research and Treatment.